Champions Oncology, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2015, compared with fiscal 2014. Although the request metadata says “2014 Q4,” this filing is an annual report for fiscal 2015, not a quarterly report.
Business context
Champions develops and sells oncology research and personalized-care services using its TumorGraft platform, which implants human tumors in immune-deficient mice. Personalized Oncology Solutions (POS) serves patients and physicians; Translational Oncology Solutions (TOS) serves pharmaceutical and biotechnology companies. TOS generated about 81% of fiscal 2015 revenue.
Financial performance and liquidity
| Metric | FY2015 | FY2014 | Change |
|---|---|---|---|
| Revenue | $8.863 million | $11.550 million | Down 23.3% |
| POS revenue | $1.663 million | $2.264 million | Down 26.5% |
| TOS revenue | $7.200 million | $9.286 million | Down 22.5% |
| Operating loss | $13.238 million | $6.260 million | Loss increased |
| Net loss | $13.140 million | $7.406 million | Loss increased |
| Net loss per share | $0.18 | $0.11 | Loss per share increased |
| Cash used in operations | $9.630 million | $3.433 million | Use increased |
- POS gross margin worsened to negative 64% from negative 21%; TOS gross margin declined to 32% from 63%.
- Research and development expense rose 114% to $4.845 million, principally for TumorBank characterization. Sales and marketing expense increased 35.8% to $4.283 million, while general and administrative expense declined to $5.340 million from $6.127 million.
- At April 30, 2015, cash and cash equivalents were $9.357 million, working capital was approximately $6.9 million, total current assets were $10.763 million and current liabilities were $3.796 million. Total liabilities were $3.988 million.
- The company reported no conventional borrowings in the balance-sheet summary; it had a laboratory-equipment capital lease with $114,000 of remaining minimum payments ($23,000 current and $91,000 long-term). Executive convertible notes totaling $2 million plus accrued interest were converted to equity in March 2015.
- Management stated that available cash was expected to fund operations through at least the first quarter of fiscal 2017, while warning that additional capital might be needed and could not be assured on acceptable terms.
Material changes and unusual items
- Revenue fell in both businesses. POS core implant and drug-panel revenue declined despite a 1% increase in implants to 245; management attributed the decline partly to fewer tests per panel. TOS revenue recognition was slowed by longer study durations and extensions.
- In March 2015, the company raised $14 million gross through a securities placement of common-stock units and warrants. The cash-flow statement reports $11.220 million of net private-placement proceeds, after issuance costs; the $2 million executive notes were separately reported as financing cash and then converted to equity.
- The placement and related amendments resulted in substantial share issuance and dilution, including anti-dilution shares for earlier investors. Warrants from earlier placements were amended, eliminating future anti-dilution provisions; the related liability was reclassified to equity. The warrant fair-value change was a non-cash benefit of $981,000, partly offset by a $586,000 warrant modification charge.
- Senior executives exchanged existing options for fewer options at a lower exercise price. The modification produced $214,000 of current-period expense and $387,000 of additional future expense. The CEO and president also accepted their fiscal-year compensation entirely in options rather than partly in cash.
- Revenue from the Teva agreement was $724,000 in FY2015 versus $194,000 in FY2014. Further milestone payments and royalties are contingent on development, clinical testing, regulatory approval and commercialization.
- Deferred revenue included $258,000 associated with licensed tumors that may need replacement under contractual terms.
Outlook, risks and contingencies
The filing provides no formal revenue or earnings guidance. Management’s stated priorities are to expand the TumorGraft platform and TumorBank, develop related data and bioinformatics, and grow POS and TOS. The company expects operating losses to continue until revenue grows sufficiently to cover costs and notes that further financing may be required.
- POS demand and economics are exposed to lengthy study timelines, unsuccessful tumor growth, negative service margins and limited evidence that mouse tumor responses predict patient outcomes.
- The TumorGraft platform is proprietary but not patented, leaving it vulnerable to imitation and competition from better-resourced companies.
- Potential changes in FDA oversight of laboratory-developed tests could require additional review, approvals, expense or delays for POS services. The company also faces laboratory licensing and other regulatory requirements.
- Operations depend on laboratory facilities and a healthy mouse population; damage, lease disputes or animal-health problems could disrupt studies and the TumorBank.
- Customer concentration is relevant: three TOS customers each contributed more than 10% of revenue in FY2015. The company also depends on continued access to capital and faces substantial dilution from equity, warrants and options.
- Registration-rights agreements provide for potential liquidated damages in specified circumstances. The company said it had not accrued such amounts and believed payment was not probable as of April 30, 2015.
Most important facts for investors to verify
- Whether post-year-end revenue, study completion timing and POS/TOS margins support a credible path toward reducing losses and cash burn.
- Whether the reported cash runway remains valid given operating cash use of $9.630 million in FY2015 and management’s stated expectation of possible future financing needs.
- The full dilution impact of the March 2015 placement, anti-dilution issuances, warrants, options and related amendments; the filing’s narrative gives differing figures for additional anti-dilution shares in different sections.
- Evidence supporting TumorGraft clinical predictability, tumor take rates and the commercial value of the TumorBank and bioinformatics investments.
- Any FDA action affecting laboratory-developed tests, and the status of contractual replacement obligations, Teva milestones and registration-rights deadlines.